Back

Mortality of individuals with antemortem genetic testing for PRNP variants in the United States, 1998-2024

Lian, Y.; Kotobelli, K.; Glisic, K.; Sprague, D. A.; Vallabh, S. M.; Appleby, B. S.; Minikel, E. V.

2025-10-05 neurology
10.1101/2025.10.03.25337271 medRxiv
Show abstract

ObjectivesTo characterize the survival of individuals with pathogenic PRNP variants -- including to estimate annual hazards, to judge the accuracy of previously reported survival data, and to evaluate the utility of public record searches in determining vital status. MethodsIn this single center cohort study, we gathered data on individuals who received positive antemortem PRNP genetic tests at the U.S. National Prion Disease Pathology Surveillance Center (NPDPSC). Genetic test results and autopsy status were queried from the NPDPSC database, and public record searches were conducted using online tools. Results404 individuals received positive genetic test results. Of 206 cases symptomatic at the time of genetic testing, 188 are likely now deceased based on typical disease duration for their genetic variants. Combined autopsy and public record searches in combination confirmed 174 of these deaths, for an estimated sensitivity of 92.6%. Of 111 autopsied individuals, evidence of death was found in public record searches for 109, a sensitivity of 98.2%. Of 198 individuals who were asymptomatic at the time of testing, 32 since died of definite or possible prion disease. Among 20 of these who underwent autopsy, public record searches confirmed deaths of 18, for a sensitivity of 90%. Among 99 E200K individuals over 936 person-years of follow-up, 18 deaths were observed, significantly fewer than 27.4 expected according to life tables based on retrospective data. The age-dependent penetrance of E200K calculated from these longitudinal data was significantly lower than that from retrospective data, with 69% penetrance by age 80 and a median age at death of 75. No significant difference was found for D178N, which appears highly penetrant, though the median age at death was numerically higher than seen in retrospective data. V210I was associated with just 2 deaths, both after age 90, consistent with minimal penetrance. DiscussionThese data support the accuracy of penetrance classifications for PRNP variants reported based on retrospective data, but may suggest an age of onset distribution shifted slightly later than that calculated retrospectively. Autopsy data and public death records in combination were sensitive and concordant, but additional prospective data should be gathered to support future preventive trials.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Neurology
44 papers in training set
Top 0.1%
18.5%
2
Journal of Neurology, Neurosurgery & Psychiatry
29 papers in training set
Top 0.1%
9.1%
3
PLOS Pathogens
721 papers in training set
Top 2%
8.2%
4
European Journal of Neurology
20 papers in training set
Top 0.1%
4.3%
5
Annals of Neurology
57 papers in training set
Top 0.5%
3.9%
6
PLOS ONE
4510 papers in training set
Top 40%
3.6%
7
Frontiers in Neurology
91 papers in training set
Top 2%
3.1%
50% of probability mass above
8
Scientific Reports
3102 papers in training set
Top 46%
2.6%
9
Neurobiology of Disease
134 papers in training set
Top 2%
2.3%
10
Brain
154 papers in training set
Top 2%
2.1%
11
BMJ Open
554 papers in training set
Top 8%
1.9%
12
Journal of Neurology
26 papers in training set
Top 0.5%
1.9%
13
Nature Medicine
117 papers in training set
Top 2%
1.7%
14
Brain Communications
147 papers in training set
Top 2%
1.7%
15
Nature Communications
4913 papers in training set
Top 52%
1.7%
16
PLOS Medicine
98 papers in training set
Top 2%
1.7%
17
Acta Neuropathologica
51 papers in training set
Top 0.7%
1.7%
18
Neurobiology of Aging
95 papers in training set
Top 1%
1.7%
19
Annals of Clinical and Translational Neurology
29 papers in training set
Top 0.6%
1.7%
20
EClinicalMedicine
21 papers in training set
Top 0.3%
1.5%
21
Movement Disorders
62 papers in training set
Top 0.8%
1.3%
22
Neuropathology and Applied Neurobiology
14 papers in training set
Top 0.4%
0.9%
23
Alzheimer's & Dementia
143 papers in training set
Top 2%
0.9%
24
eBioMedicine
130 papers in training set
Top 3%
0.9%
25
Frontiers in Neuroscience
223 papers in training set
Top 7%
0.7%
26
Science Translational Medicine
111 papers in training set
Top 6%
0.7%
27
BMC Medicine
163 papers in training set
Top 8%
0.6%
28
JAMA Network Open
127 papers in training set
Top 5%
0.6%